Business Description
JCR Pharmaceuticals Co Ltd
ISIN : JP3701000006
Share Class Description:
JCRRF: Ordinary SharesDescription
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.5 | |||||
| Debt-to-EBITDA | 21.14 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.99 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.1 | |||||
| 3-Year EBITDA Growth Rate | -0.5 | |||||
| 3-Year EPS without NRI Growth Rate | -6.9 | |||||
| 3-Year FCF Growth Rate | 36.4 | |||||
| 3-Year Book Growth Rate | 13.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 2.22 | |||||
| 9-Day RSI | 18.54 | |||||
| 14-Day RSI | 34.72 | |||||
| 6-1 Month Momentum % | -12.45 | |||||
| 12-1 Month Momentum % | -49.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | |||||
| Quick Ratio | 0.98 | |||||
| Cash Ratio | 0.54 | |||||
| Days Inventory | 759.35 | |||||
| Days Sales Outstanding | 165.86 | |||||
| Days Payable | 37.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.82 | |||||
| 3-Year Dividend Growth Rate | -3.9 | |||||
| Forward Dividend Yield % | 2.82 | |||||
| 5-Year Yield-on-Cost % | 8.27 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | -0.85 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.44 | |||||
| Operating Margin % | -0.58 | |||||
| Net Margin % | -1.24 | |||||
| FCF Margin % | 20.25 | |||||
| ROE % | -0.78 | |||||
| ROA % | -0.42 | |||||
| ROIC % | -0.23 | |||||
| ROC (Joel Greenblatt) % | -0.65 | |||||
| ROCE % | -0.45 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 20.22 | |||||
| Shiller PE Ratio | 15.11 | |||||
| PS Ratio | 2.06 | |||||
| PB Ratio | 1.29 | |||||
| Price-to-Tangible-Book | 1.36 | |||||
| Price-to-Free-Cash-Flow | 10.09 | |||||
| Price-to-Operating-Cash-Flow | 7.82 | |||||
| EV-to-EBIT | -257.14 | |||||
| EV-to-Forward-EBIT | 18.07 | |||||
| EV-to-EBITDA | 61.8 | |||||
| EV-to-Forward-EBITDA | 14.63 | |||||
| EV-to-Revenue | 2.36 | |||||
| EV-to-Forward-Revenue | 3.82 | |||||
| EV-to-FCF | 11.51 | |||||
| Price-to-Projected-FCF | 1.69 | |||||
| Price-to-DCF (FCF Based) | 0.28 | |||||
| Price-to-Median-PS-Value | 0.37 | |||||
| Price-to-Net-Current-Asset-Value | 8.62 | |||||
| Earnings Yield (Greenblatt) % | -0.39 | |||||
| FCF Yield % | 9.9 | |||||
| Forward Rate of Return (Yacktman) % | 12.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:JCRRF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JCR Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 237.84 | ||
| EPS (TTM) ($) | -0.027 | ||
| Beta | 0.59 | ||
| Volatility % | 46.78 | ||
| 14-Day RSI | 34.72 | ||
| 14-Day ATR ($) | 0.000189 | ||
| 20-Day SMA ($) | 4.57 | ||
| 12-1 Month Momentum % | -49.45 | ||
| 52-Week Range ($) | 4.3004 - 9.04 | ||
| Shares Outstanding (Mil) | 125.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JCR Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JCR Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
JCR Pharmaceuticals Co Ltd Frequently Asked Questions
What is JCR Pharmaceuticals Co Ltd(JCRRF)'s stock price today?
The current price of JCRRF is $4.57. The 52 week high of JCRRF is $9.04 and 52 week low is $4.30.
When is next earnings date of JCR Pharmaceuticals Co Ltd(JCRRF)?
The next earnings date of JCR Pharmaceuticals Co Ltd(JCRRF) is .
Does JCR Pharmaceuticals Co Ltd(JCRRF) pay dividends? If so, how much?
The Dividend Yield %  of JCR Pharmaceuticals Co Ltd(JCRRF) is 2.82% (As of Today), Highest Dividend Payout Ratio of JCR Pharmaceuticals Co Ltd(JCRRF) was 0.66. The lowest was 0.16. And the median was 0.38. The  Forward Dividend Yield % of JCR Pharmaceuticals Co Ltd(JCRRF) is 2.82%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers